ICU Medical price target lowered to $187 from $197 at Raymond James

Raymond James lowered the firm’s price target on ICU Medical (ICUI) to $187 from $197 and keeps a Strong Buy rating on the shares. ICU Medical’s Q1 results were well ahead of consensus, highlighted by 10% revenue growth, the analyst tells investors in a research note. While comps will get tougher, ICU’s cadence of innovation on the pump side lends more confidence in the top-line growth profile over the next couple of years, the firm says.